AMERICAN PHARMACEUTICAL ASSOCIATION
The National Professional Society of Pharmacists

February 25, 1974

Honorable Gaylord Nelson
United States Senator
Senate Select Committee on Small Business
Room 424
Old Senate Office Building
Washington, DC 20510

Dear Senator Nelson:

During the hearings of the Monopoly Subcommittee on February 21, I referred to a number of documents or matters of information in the course of my testimony. You requested that I submit copies of pertinent material to you for the Subcommittee record.

On this basis, I am herewith enclosing the following items:

a. Copies of letters dated September 30, 1969 and October 8, 1969 which I sent (in my capacity at the time as Director of the National Formulary) to Defense Personnel Support Center (DPSC) staff. In particular, I quoted during my testimony from the latter half of the first paragraph which appears on page three of the September 30 letter and which explains to the DPSC staff the fact that a weight variation test and a content uniformity test in the case of Hyaluronidase for Injection would be meaningless and redundant.

b. Copies of pertinent pages of "Defense Medical Purchase Discription" documents issued by DPSC. These include identification of the drug dosage forms involved, as well as the specific requirements or specifications which I quoted in my testimony as being -- in my opinion and based upon knowledge available to me -- unnecessary and meaningless from a medical or drug quality standpoint. These examples were cited in the context of the discussion relative to examples of DPSC requirements which serve to eliminate competition among bidders by being structured in a manner that they describe a single manufacturer's particular drug product.

2215 CONSTITUTION AVENUE, N.W., WASHINGTON, D.C. 20037 • (202) 628-4410
CABLE ADDRESS: AMPHARMA